Market Movers (8-K)
NASDAQ
Mobia Medical announced a robust second quarter for 2026, with revenue soaring 102% year-over-year to $13.5 million, driven by increased adoption of its Vivistim System.
Better than expected
Capital raise
NASDAQ
Mobia Medical, Inc. has expanded its Board of Directors by appointing Dr. Myriam J. Curet, a seasoned executive with extensive experience in medical technology and surgery.
NASDAQ
Mobia Medical, Inc. has expanded its Board of Directors to seven members with the appointment of Dr. Reza Zadno, who will also serve on the Compensation Committee.
Quarterly Earnings (10-Q)
NASDAQ
Mobia Medical, Inc. (MOBI) announced a significant increase in revenue for the second quarter of 2026, driven by strong adoption of its Vivistim System, following its successful Initial Public Offering.
Capital raise
Better than expected
Insider Trading (Form 4)
See all →NASDAQ
Chase C. Leavitt, SEE REMARKS of Mobia Medical, Inc., purchased 2,000 shares of common stock on September 11, 2026 for $10.30 per share.
NASDAQ
Prashant B. Rawat, Chief Operating Officer of Mobia Medical, Inc., reported multiple transactions in common stock on September 2, 2026.
NASDAQ
Casey M Tansey, a Director of Mobia Medical, Inc., purchased 16,441 shares of common stock on August 18, 2026 for $12.07 per share.
NASDAQ
Casey M Tansey, a Director of Mobia Medical, Inc., purchased 68,559 shares of common stock on August 13, 2026.
NASDAQ
Myriam Curet, a Director of Mobia Medical, Inc., reported multiple transactions in common stock on July 30, 2026.
NASDAQ
Reza Zadno, a Director of Mobia Medical, Inc., reported multiple transactions in common stock on July 14, 2026.
Schedule 13G - Passive Investments
NASDAQ
U.S. Venture Partners and related entities have disclosed their beneficial ownership of Mobia Medical, Inc. common stock, representing a significant stake.